1. Home
  2. SGU vs CMPX Comparison

SGU vs CMPX Comparison

Compare SGU & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGU

Star Group L.P.

N/A

Current Price

$12.88

Market Cap

418.3M

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.25

Market Cap

371.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGU
CMPX
Founded
1995
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
418.3M
371.0M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
SGU
CMPX
Price
$12.88
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
22.1K
3.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
5.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,784,418,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$934.41
P/E Ratio
$6.70
N/A
Revenue Growth
1.04
N/A
52 Week Low
$11.37
$1.61
52 Week High
$13.53
$6.88

Technical Indicators

Market Signals
Indicator
SGU
CMPX
Relative Strength Index (RSI) 54.66 53.24
Support Level $12.33 $1.88
Resistance Level $12.85 $2.47
Average True Range (ATR) 0.27 0.10
MACD 0.03 0.06
Stochastic Oscillator 73.89 84.85

Price Performance

Historical Comparison
SGU
CMPX

About SGU Star Group L.P.

Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: